Your browser doesn't support javascript.
loading
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Marconi, Vincent C; Ramanan, Athimalaipet V; de Bono, Stephanie; Kartman, Cynthia E; Krishnan, Venkatesh; Liao, Ran; Piruzeli, Maria Lucia B; Goldman, Jason D; Alatorre-Alexander, Jorge; de Cassia Pellegrini, Rita; Estrada, Vicente; Som, Mousumi; Cardoso, Anabela; Chakladar, Sujatro; Crowe, Brenda; Reis, Paulo; Zhang, Xin; Adams, David H; Ely, E Wesley.
Affiliation
  • Marconi VC; Emory University School of Medicine, Rollins School of Public Health and the Emory Vaccine Center, Atlanta, GA, USA; Atlanta Veterans Affairs Medical Center, Decatur, GA, USA. Electronic address: vcmarco@emory.edu.
  • Ramanan AV; Translational Health Sciences, University of Bristol, Bristol, UK; Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol, UK.
  • de Bono S; Eli Lilly and Company, Indianapolis, IN, USA.
  • Kartman CE; Eli Lilly and Company, Indianapolis, IN, USA.
  • Krishnan V; Eli Lilly and Company, Indianapolis, IN, USA.
  • Liao R; Eli Lilly and Company, Indianapolis, IN, USA.
  • Piruzeli MLB; Eli Lilly and Company, Indianapolis, IN, USA.
  • Goldman JD; Swedish Center for Research and Innovation, Swedish Medical Center, Providence St Joseph Health, Seattle, WA, USA; Division of Allergy and Infectious Disease, Department of Medicine, University of Washington, Seattle, WA, USA.
  • Alatorre-Alexander J; Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico.
  • de Cassia Pellegrini R; Pesquisare/Santo André, Brazil and Hospital Beneficência Portuguesa de São Caetano do Sul / São Caetano do Sul, Brazil.
  • Estrada V; Hospital Clinico San Carlos-IdiSSC, Universidad Complutense, Madrid, Spain.
  • Som M; Oklahoma State University Medicine, Internal Medicine-Houston Center, Tulsa, OK, USA.
  • Cardoso A; Eli Lilly and Company, Indianapolis, IN, USA.
  • Chakladar S; Eli Lilly and Company, Indianapolis, IN, USA.
  • Crowe B; Eli Lilly and Company, Indianapolis, IN, USA.
  • Reis P; Eli Lilly and Company, Indianapolis, IN, USA.
  • Zhang X; Eli Lilly and Company, Indianapolis, IN, USA.
  • Adams DH; Eli Lilly and Company, Indianapolis, IN, USA.
  • Ely EW; Critical Illness, Brain Dysfunction, and Survivorship Center (CIBS), Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine at Vanderbilt University Medical Center, Nashville, TN, USA; Tennessee Valley Veteran's Affairs Geriatric Research Education Clinical Center (GRECC)
Lancet Respir Med ; 9(12): 1407-1418, 2021 12.
Article in En | MEDLINE | ID: mdl-34480861
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Purines / Pyrazoles / Sulfonamides / Azetidines / COVID-19 Drug Treatment Type of study: Clinical_trials Limits: Adult / Humans Country/Region as subject: America do norte / America do sul / Asia / Europa Language: En Journal: Lancet Respir Med Year: 2021 Document type: Article Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Purines / Pyrazoles / Sulfonamides / Azetidines / COVID-19 Drug Treatment Type of study: Clinical_trials Limits: Adult / Humans Country/Region as subject: America do norte / America do sul / Asia / Europa Language: En Journal: Lancet Respir Med Year: 2021 Document type: Article Country of publication: United kingdom